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Abstract : This study investigated the possibility of an injectable bone substitute consisting of methylcellulose
aqueous solutions and poly lactide-co-glycolide acid/hydroxyapatite (PLGA/HA) composite microspheres contain-
ing sustained releasing antibiotics. HA nanoparticles were synthesized by coprecipitation. PLGA/HA composite
microspheres were prepared by oil-in-water emulsion/solvent evaporation with tetracycline. They were mixed with
a 2% (w/v) aqueous solution of methylcellulose. The particle size of the composite microspheres increased linearly
with increasing PLGA concentration from 17.8±4.5 to 185.4±29.5 µm. As the size of PLGA/HA composite micro-
spheres increased, the content of tetracycline increased from 0.8% to 70.3%. The release rate of tetracycline
decreased with increasing size of the composite microspheres. Tetracycline exhibited a burst release with nearly
100% escape within 24 hrs when the PLGA concentration was less than 20%. Sustained continuous release until 2
weeks when PLGA content was 20%. The gelation temperature of methylcellulose can be adjusted to normal body
temperature when NaCl content exceeds 5%. PLGA/HA composite microspheres mixed with a methylcellulose
aqueous solution was easily and completely ejected through an 18G needle when the mixing ratio was below 100%.
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1. Introduction
There is an increasing demand for bone substitutes in the
field of orthopedic surgery due to the increasing use of
advanced procedures in reconstructive surgery after various
traumatic pathologies and iatrogenic bone losses secondary to
bone resections for tumors, infections or pseudoarthroses. In
addition, the increasing number of elderly patients or
individuals with various systemic pathologies and biological
shortcomings related to the bone healing processes often
necessitates the use of bone substitutes as an adjuvant therapy
to prosthetic implants in order to improve the level of biological
fixation and osseointegration processes.
1,2
Recently, injectable gels have been developed in orthopedics.
These gels can fill defects of any shape, can incorporate various
therapeutic agents, and do not contain residual solvents. Hence,
they can reduce surgery time, minimize damaging effects,
reduce the size of scars, decrease post-operative pain, and allow
patients to achieve a rapid recovery. Several injectable
biomaterials have been developed including collagen,3
polyethylene oxide,4 calcium alginate,5 and fibrin glue.6,7
Hydroxyapatite (HA) is a well-known biomaterial used as a
bone substitute to fill bone defects and as a coating agent on
biomedical  implants .  Methylcel lulose  (MC) and
hydroxypropylmethylcellulose (HPMC) have the unique
property of reversible thermogelation. Upon cooling, the
gelation process is completely reversed and the gel formed
reverts to the sol state. The temperature at which the gelation
process begins as well as the strength of the gel formed depend
on the type and degree of substitution of the gum, molecular
weight, concentration, and the presence of electrolytes.
8
Many studies have shown benefits of in vitro and in vivo
associations of therapeutic agents using drug delivery systems
(DDS).
9 Controlled DDS can help optimize the therapeutic
efficiency and reduce serious side effects.
10,11
Poly[DL-lactide-co-glycolide](PLGA)-based microparticles
can help to accurately control the drug release kinetics over
periods of days to months, and can be administered easily using
standard syringes or needles with complete biodegradability
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and good biocompatibility. The size of the microsphere, which
is a key factor in the release rate, might have a significant effect
on product performance and safety. The particle size can also
influence the injectability of the product.
The aim of this study was to assess the potential of a MC
aqueous solution containing PLGA/HA composite
microspheres and antibiotics as a sustained drug release-bone
substitute.
2. Materials and Methods
Needle-shaped HA nanoparticles, 20 nm in width and 100 nm
in length, were synthesized by coprecipitation. A 0.3 M aqueous
solution of (NH4)2·HPO4 was added drop wise to a 0.5 M
aqueous solution of CaCl2 with vigorous stirring at 10,000 rpm.
The pH of the reacted solution was adjusted to pH 10 using a
NH4OH solution and the temperature was maintained at 60
oC.
The coprecipitated HA was filtered, washed with NH4Cl2 and
freeze-dried.
The PLGA/HA composite microspheres were prepared by
oil-in-water (O/W) emulsion/solvent evaporation. Various
PLGA concentrations ranging from 2.5 to 20% were dissolved
in dichloromethane (DCM), as shown in Table 1. The resulting
solution was mixed with HA and tetracycline (TC) at a fixed
ratio of 10:1:1 (PLGA:HA:TC). The resulting mixture was
poured into an aqueous solution of 2% polyvinyl alcohol (PVA)
and homogenized at 3,000 rpm. After rotary evaporation under
vacuum, the PLGA/HA composite microspheres were washed
and freeze-dried. The morphology and the average size of the
composite microspheres were determined using an optical
microscope (Olympus CK2, Olympus optical, Japan).
The release rate of TC from the composite microspheres was
determined using a UV/Visible Spectrophotometer (UVD-
3200, LaboMed, USA). 200 mg of the composite microspheres
were immersed into 20 mL of saline and shaken continuously
at 37oC. At set time intervals, the intensity of the absorption
spectra at 275 nm of the saline was measured using a UV/
Visible Spectrophotometer.
The PLGA/HA composite microspheres containing TC were
mixed with a 2% (w/v) aqueous solution of methylcellulose
(MC; viscosity of 400 cP). The mixing ratio of the
microspheres/solution was varied from 40/60 to 60/40 (w/v).
Before mixing, the gelation temperature of the 2% MC aqueous
solution was adjusted to normal body temperature by adding
NaCl. The gelation temperature according to the amount of
NaCl added (up to 6%) was determined by examining the
rheological behavior at temperatures up to 60
oC using a fluid
rheometer (RVDV-III, Brookfield, USA).
In order to verify the optimum injection condition through a
needle, the injectability of the MC aqueous solution containing
the dispersed PLGA/HA composite microspheres was
measured using a slight modification of the method reported by
Bohner and Baroud.
12 A syringe with an 18G needle was filled
with 1 mL of the aqueous solutions of MC containing the
PLGA/HA composite microspheres. The needle was then
placed in a cylinder-shaped holster, which was attached to a
universal test machine (AG-5000G, Shimadzu, Japan). A
stainless steel rod, 4 mm in diameter, was pressed vertically on
the gasket at a crosshead speed of 10 mm/min, and the load-
displacement curves were obtained. 
3. Results
Fig 1 shows a representative optical micrograph of the
PLGA/HA composite microspheres. All the particles had a
spherical shape. Fig 2 shows the particle size according at
PLGA concentrations up to 20%. The particle size of the
composite microspheres increased linearly with increasing
PLGA concentration from 17.8±4.5 to 185.4±29.5 µm. It is
believed that at a fixed stirring shear force, the higher
concentration of PLGA increase the viscosity of the oil phase.
Table 1. Particle size and content of tetracycline in PLGA/HA
microspheres
Sample 
code
PLGA concentration 
(% w/v)
Particle size 
(mm)
Content of TC 
(%)
PHM1 2.5 17.8±4.5 0.8
PHM2 5 48.7±9.4 10.6
PHM3 10 96.3±17.7 21.8
PHM4 20 185.4±29.5 70.3
Figure 1. Representative image of PLGA/HA microspheres
(scale bar = 100 µm).
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This makes it difficult for small droplets to form because it is
well known that the size of the emulsion droplets depends on
the balance between the stirring shear force and the level of
droplet cohesion. This trend is in agreement with the findings
reported by Klose et al. in that DCM diffuses from the solution
into the water carrying some PLGA molecules with it.
13 The
amount of DCM increases with increasing PLGA
concentration with the other conditions fixed, which increases
particle size.
14 The TC content increased from 0.8% to 70.3%
with increasing particle size of the PLGA/HA composite
microspheres, as shown in (Table 1). 
Fig 3 shows the effect of the size of the PLGA/HA composite
microspheres on the release rate of TC in saline. A high initial
burst phenomenon was observed with the exception of PHM4.
The relative release rates of TC increased up to 100% within 24
hrs except for PHM4. This means that the relative release rate
decreased with increasing particle size of the composite
microspheres. Fig 4 shows that PHM4 has a sustained release
rate of 80% for 2 weeks.
Fig 5 shows the rheological behavior of MC at various NaCl
concentrations. The viscosity increased with increasing
temperature. The temperature at which the viscosity of the
solution increased suddenly is regarded as the gelation
temperature. The gelation temperature of MC decreased from
54
oC to 32.5oC with increasing amount of NaCl added,
concentrations of 0, 2, 4, 5, 6% NaCl where tested. The gelation
temperature was lower than body temperature when the amount
Figure 2. Effect of PLGA concentration on the particle size of
PLGA/HA microspheres.
Figure 3. Cumulative release of tetracycline from PLGA/HA
composite microspheres with various amount of PLGA in saline
at 37oC.
Figure 4. Cumulative release of tetracycline from PLGA/HA
composite microspheres with 20% of PLGA up to 2 weeks in
saline at 37oC.
Figure 5. Rheological curves of 2% methylcellulose aqueous solu-
tion blended with various amount of NaCl up to 6%.
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of NaCl in MC exceeded 5%. 
Fig 6 shows the load-displacement curves of the MC
solutions containing the PLGA/HA composite microspheres
through a needle from a syringe. The ratio between the PLGA/
HA composite microspheres and the MC solutions was varied
from 66.7% to 150.0% (w/v) with the PLGA concentration
fixed at 5%. When the ratio was 66.7%, the MC solutions
containing the PLGA/HA composite microspheres were easily
and completely ejected through the 18G needle using a small
load. The load needed to eject the mixtures increased with
increasing particle/solution ratio with uninjected amounts
remaining inside the syringe at the higher ratios.
4. Discussion
This study evaluated the potential of an injectable bone
substitute consisting of a MC aqueous solution and the PLGA/
HA composite microspheres containing sustained release
antibiotics.
PLGA/HA composite microspheres containing TC were
used to examine the drug release profiles according to the
change in the size of the composite microspheres. It is clear that
the release rate of TC decreased with increasing size of the
composite microspheres. PHM1, PHM2, and PHM3 showed
an initial burst stage and the drug was released completely
within 24 hrs, whereas only 17% of TC was released without
the initial high burst in the case of PHM4. PHM4 showed
sustained release of TC for 2 weeks, which can be explained by
properties of both PLGA and TC as follows.
Firstly, the rate of PLGA degradation increases with
increasing particle size, irrespective of the presence or absence
of the antibiotics. This autocatalytic effect is due to the increase
in the diffusion pathways for the acids generated from the
release medium with increasing particle size. The decrease in
pH becomes more pronounced and the ester bond cleavage is
accelerated, followed by an increase in the shorter chain
degradation products. Therefore, the average molecular weight
of PLGA in the large particles decreases more rapidly than in
the small ones.
Another explanation is related to the release mechanism of TC
from the PLGA/HA composite microspheres i.e. diffusion.
15
This means that the concentration gradient of TC should decrease
with increasing length of the diffusion pathway of larger spheres.
The absence of this “increased diffusion pathway length effect”
can accelerate the rate of polymer degradation.
16 The resulting
release rate of TC is a combination of the above two phenomena.
Encapsulation is a common way of controlling the release of
various therapeutic agents,
17 such as antibiotics, anticancer
drugs, growth factors
18 or steroid hormones.19 However, these
DDS do not allow drug release for more than a few days. In this
study, the PLGA/HA composite microspheres allowed constant
release of TC for more than two weeks.
The PLGA/HA microspheres containing TC were dispersed
in the MC solutions in order to achieve appropriate injectability,
which was the aim of this study. The content of PLGA/HA
composite microspheres in the MC solution was found to be a
critical factor for injectability. However, it is expected that a
larger size and higher particle content in the MC solution can be
injected if a larger needle gauge is used.
NaCl is added to the MC solution to adjust the gelation
temperature to human body temperature. When the amount of
NaCl exceeded 5%, the gelation temperature was less than body
temperature. There is a stronger interaction between Cl- and a
water molecule than between water molecules. Therefore, NaCl
destroys some of the original hydrogen-bonding network formed
by water. This effect is similar to increasing the temperature. The
Figure 6. Load-displacement curves of methylcellulose aqueous
solution dispersed with various amount of PLGA/HA composite
microspheres through a syringe.
Table 2. Gelation temperature and fluidity of methylcellulose
aqueous solution according to the amount of NaCl
Sample 
code
Concentration 
of NaCl (%)
Gelation 
temperature (oC)
Fluidity
MC 0 54.0 O
MC2 2 44.4 O
MC4 4 38.4 O
MC5 5 35.7 X
MC6 6 32.5 X
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competition for water molecules from NaCl, and the NaCl-
induced destruction of the hydrogen bonds between the MC
chains and water molecule decreases the MC solubility in water.
As a result, at the same temperature, there are more hydrophobic
aggregates of MC in the NaCl-containing MC solution than in
the NaCl-free one, which leads to stronger light scattering and a
lower transmittance at a given temperature. Therefore, the
clouding point of the NaCl-containing samples appears at a lower
temperature. The increase in the NaCl content results in fewer
free water molecules available around the MC chains and a
stronger hydrophobic environment for MC, which causes
turbidity of the MC at a given temperature.
5. Conclusion
This study investigated the possibility of an injectable bone
substitute consisting of MC aqueous solutions and PLGA/HA
composite microspheres for sustained release of antibiotics. 
The particle size of the composite microspheres increased
linearly with increasing PLGA concentration from 17.8±4.5 to
185.4±29.5 µm. The TC content increased from 0.8% to 70.3%
with increasing particle size of the PLGA/HA composite
microspheres. The release rate of TC decreased with increasing
size of the composite microspheres. At a PLGA concentration
< 20%, the TC rapidly diffused out and was almost completely
exhausted within 24 hrs, while the rate of diffusion was
sustained for 2 weeks when the PLGA content was 20%.
The gelation temperature of MC was lower than body
temperature when the NaCl content exceeded 5%. The PLGA/
HA composite microspheres mixed with a MC aqueous
solution at a mixing ratio < 100% could be ejected through an
18G needle with little load.
It could be concluded that the injectable bone substitute
tested were can potentially be used for sustained release of
antibiotics and bone tissue regeneration.
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